Recipharm reaches agreement with LobSor Pharmaceuticals to manufacture LECIGON (TM), a proprietary treatment for advanced Parkinson’s disease

Recipharm and LobSor Pharmaceuticals, an Uppsala-based pharmaceutical company focusing on the development of innovative systems to treat symptoms of advanced Parkinson’s disease (APD), are pleased to announce the formation of a manufacturing agreement for LECIGON™.  As part of the agreement, Recipharm will have exclusive manufacturing rights for volumes representing first three years of commercial sales.  Recipharm will also support development costs against a mark-up on manufacturing prices, up to a certain volume, when LECIGON is produced for commercial sales.  

This agreement is a follow-on to an established collaboration between LobSor and Recipharm for the development and the manufacturing of batches for the recently completed clinical trial.

Carl-Johan Spak, EVP Development & Technology, Recipharm, commented: “We are extremely pleased to have developed our collaborative partnership with LobSor Pharmaceuticals and to have signed an agreement for the future commercial manufacturing of LECIGON, especially as this is a new, innovative drug, which we believe provides a clear benefit to patients with advanced Parkinson’s disease.”

Roger Bolsöy, Managing Director of LobSor Pharmaceuticals said “It is well known that pharmaceutical development is costly and can be cumbersome for a small company. Recipharm is one of our most important strategic partners for the development of our first pharmaceutical product, with whom we have been able to find creative collaboration models to secure the initiation of the LECIGON project. I am impressed that such a large organization as Recipharm has been able to show such entrepreneurial spirit and flexibility to facilitate the development of a company from the early stages through to commercialization”.

For more information contact:
Carl-Johan Spak, EVP Development & Technology Recipharm, carl-johan.spak@recipharm.com, +46 8 602 53 13                   

Roger Bolsöy, Managing Director LobSor Pharmaceuticals, Roger.bolsoy@LSMgroup.se, +46 72 222 44 08

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm. 

For more information on Recipharm and our services, please visit www.recipharm.com

About LobSor Pharmaceuticals
LobSor Pharmaceuticals is privately owned via LobSor Holding AB and based in Uppsala, Sweden. The founders and main owners of the company, Roger Bolsöy and Ulf Rosén have extensive experience in the development, sales and marketing of pharmaceuticals and medical devices – with a particular focus on advanced Parkinson’s disease. The first product – LECIGON has been developed in close collaboration with Recipharm, TFS International and internationally renowned clinical experts – together with active support from investors.

 

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden,  Telephone 46 8 602 52 00,  Fax  46 8 81 87 03

www.recipharm.com

About Us

About RecipharmRecipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 5 000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com

Subscribe

Documents & Links

Quotes

We are extremely pleased to have developed our collaborative partnership with LobSor Pharmaceuticals and to have signed an agreement for the future commercial manufacturing of LECIGON, especially as this is a new, innovative drug, which we believe provides a clear benefit to patients with advanced Parkinson’s disease
Carl-Johan Spak
It is well known that pharmaceutical development is costly and can be cumbersome for a small company. Recipharm is one of our most important strategic partners for the development of our first pharmaceutical product, with whom we have been able to find creative collaboration models to secure the initiation of the LECIGON project.
Roger Bolsöy